$0.9637
-0.02-1.66%
At close: -
$0.9901
0.032.74%
After Hours: 7:36 PM EDT
Comments
Loading...
Atossa Therapeutics (ATOS) Forecast
NewsEarningsAtossa Therapeutics (ATOS) OptionsGuidanceDividendsAnalyst RatingsInsider TradesShort InterestAtossa Therapeutics (NASDAQ:ATOS) Stock Quotes, Forecast and News Summary
Atossa Therapeutics Stock (NASDAQ: ATOS) stock price, news, charts, stock research, profile.
Compare
EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
EPS worse than industry
FAQ
How do I buy Atossa Therapeutics (ATOS) stock?
You can purchase shares of Atossa Therapeutics (NASDAQ:ATOS) through any online brokerage.
Who are Atossa Therapeutics (ATOS) competitors?
Other companies in Atossa Therapeutics’s space includes: Cabaletta Bio (NASDAQ:CABA), Galectin Therapeutics (NASDAQ:GALT), Monopar Therapeutics (NASDAQ:MNPR), PepGen (NASDAQ:PEPG) and Tonix Pharmaceuticals (NASDAQ:TNXP).
What is the forecast, or price target, for Atossa Therapeutics (ATOS) stock?
Atossa Therapeutics has a consensus price target of $7.00.
What is the current price for Atossa Therapeutics (ATOS)?
The stock price for Atossa Therapeutics (NASDAQ: ATOS) is $0.9901 last updated December 20, 2024 at 7:36 PM EST.
Does Atossa Therapeutics (ATOS) pay a dividend?
There are no upcoming dividends for Atossa Therapeutics.
When is Atossa Therapeutics (NASDAQ:ATOS) reporting earnings?
Atossa Therapeutics’s Q3 earnings are confirmed for Tuesday, November 12, 2024.
Is Atossa Therapeutics (ATOS) going to split?
There is no upcoming split for Atossa Therapeutics.
What sector and industry does Atossa Therapeutics (ATOS) operate in?
Atossa Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.